News stories about Irhythm Technologies (NASDAQ:IRTC) have trended somewhat positive this week, according to Accern Sentiment Analysis. The research firm ranks the sentiment of media coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Irhythm Technologies earned a daily sentiment score of 0.18 on Accern’s scale. Accern also assigned news headlines about the company an impact score of 44.1488281225467 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
Several equities analysts recently commented on the company. BidaskClub upgraded Irhythm Technologies from a “hold” rating to a “buy” rating in a research report on Friday, January 5th. Canaccord Genuity boosted their target price on Irhythm Technologies from $55.00 to $59.00 and gave the stock a “buy” rating in a research report on Thursday, November 2nd. ValuEngine upgraded Irhythm Technologies from a “sell” rating to a “hold” rating in a research report on Saturday, October 21st. Royal Bank of Canada assumed coverage on Irhythm Technologies in a research report on Monday, December 4th. They set an “outperform” rating and a $79.00 target price for the company. Finally, Dougherty & Co assumed coverage on Irhythm Technologies in a research report on Friday, December 1st. They set a “neutral” rating for the company. One research analyst has rated the stock with a sell rating, two have given a hold rating and four have given a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus target price of $65.25.
Irhythm Technologies (NASDAQ IRTC) opened at $62.75 on Friday. Irhythm Technologies has a 52-week low of $28.94 and a 52-week high of $64.10. The company has a debt-to-equity ratio of 0.38, a quick ratio of 7.57 and a current ratio of 7.65. The company has a market capitalization of $1,460.00 and a PE ratio of -52.73.
In other news, CFO Matthew C. Garrett sold 42,910 shares of the company’s stock in a transaction dated Friday, January 5th. The stock was sold at an average price of $59.17, for a total value of $2,538,984.70. Following the completion of the transaction, the chief financial officer now directly owns 36,085 shares in the company, valued at approximately $2,135,149.45. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Kevin M. King sold 60,000 shares of the company’s stock in a transaction dated Monday, November 6th. The stock was sold at an average price of $51.85, for a total value of $3,111,000.00. Following the completion of the transaction, the insider now owns 103,042 shares of the company’s stock, valued at $5,342,727.70. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 536,533 shares of company stock valued at $28,333,506. 23.30% of the stock is owned by company insiders.
TRADEMARK VIOLATION WARNING: This news story was originally posted by Ticker Report and is the property of of Ticker Report. If you are viewing this news story on another website, it was copied illegally and republished in violation of US & international trademark and copyright laws. The correct version of this news story can be accessed at https://www.tickerreport.com/banking-finance/3148568/somewhat-favorable-news-coverage-somewhat-unlikely-to-impact-irhythm-technologies-irtc-stock-price.html.
About Irhythm Technologies
iRhythm Technologies, Inc is a United States-based digital health company. The Company develops and commercializes solutions that integrate biosensor technology, patient data, analytics and medical expertise. The Company offers flagship solution, the ZIO Service. Its ZIO Service consists of the ZIO XT Patch, algorithms and the ZIO Report.
Receive News & Ratings for Irhythm Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Irhythm Technologies and related companies with MarketBeat.com's FREE daily email newsletter.